The increasing knowledge of disease biology, along with the development of better diagnostic and prognostic tools and newer and more effective drugs, have paved the way for a revolution in today’s approach to multiple myeloma. The constantly expanding treatment armamentarium for both newly diagnosed and relapse myeloma patients has led to a dramatic improvement in their survival, but has also challenged myeloma physicians to identify the most appropriate treatment strategy and drug-sequencing among all the data generated by clinical trials. Importantly, most of the decisions taken in the clinical practice rely on data generated by clinical trials, that notoriously enroll a pre-selected population that does not entirely represent “real-life” patients, often excluding older and frail ones, patients with comorbidities and impaired organ function and those with aggressive diseases, such as plasma cell leukemias and extramedullary myelomas.
In this light, generating data on the availability and applicability of new diagnostic techniques and prognostic markers (minimal residual disease, PET-CT, MRI) as well as on the translation of the results of approved drugs and combinations from clinical trials into a “real-life” scenario is highly needed to clearly weigh and evaluate the impact of all the innovations concerning the approach to multiple myeloma brought into clinical practice from controlled studies.
In this collection, we welcome the submission of Review, Mini-Review and Original Research articles that cover, but are not limited, to the following topics:
1. Treatment strategies for newly diagnosed and relapsed/refractory patients with a focus on “real-life” data
2. Application and validation of diagnostic and prognostic tools both inside and outside the bone marrow (MRD, PET-CT, MRI)
3. Application and validation of risk stratification scores (e.g. genetic markers, geriatric assessment) in patients treated with novel agents
4. Pre-clinical and clinical data concerning the use of current treatment approaches on older patients and patients with plasma-cell leukemia and extramedullary disease
5. Impact of Covid-19 on myeloma patients and anti-myeloma strategies
Kindly note, Dr. Paola Tacchetti has received honoraria from Janssen, Bristol Myers Squibb/Celgene, Amgen, Takeda, AbbVie, Sanofi and Oncopeptides.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The increasing knowledge of disease biology, along with the development of better diagnostic and prognostic tools and newer and more effective drugs, have paved the way for a revolution in today’s approach to multiple myeloma. The constantly expanding treatment armamentarium for both newly diagnosed and relapse myeloma patients has led to a dramatic improvement in their survival, but has also challenged myeloma physicians to identify the most appropriate treatment strategy and drug-sequencing among all the data generated by clinical trials. Importantly, most of the decisions taken in the clinical practice rely on data generated by clinical trials, that notoriously enroll a pre-selected population that does not entirely represent “real-life” patients, often excluding older and frail ones, patients with comorbidities and impaired organ function and those with aggressive diseases, such as plasma cell leukemias and extramedullary myelomas.
In this light, generating data on the availability and applicability of new diagnostic techniques and prognostic markers (minimal residual disease, PET-CT, MRI) as well as on the translation of the results of approved drugs and combinations from clinical trials into a “real-life” scenario is highly needed to clearly weigh and evaluate the impact of all the innovations concerning the approach to multiple myeloma brought into clinical practice from controlled studies.
In this collection, we welcome the submission of Review, Mini-Review and Original Research articles that cover, but are not limited, to the following topics:
1. Treatment strategies for newly diagnosed and relapsed/refractory patients with a focus on “real-life” data
2. Application and validation of diagnostic and prognostic tools both inside and outside the bone marrow (MRD, PET-CT, MRI)
3. Application and validation of risk stratification scores (e.g. genetic markers, geriatric assessment) in patients treated with novel agents
4. Pre-clinical and clinical data concerning the use of current treatment approaches on older patients and patients with plasma-cell leukemia and extramedullary disease
5. Impact of Covid-19 on myeloma patients and anti-myeloma strategies
Kindly note, Dr. Paola Tacchetti has received honoraria from Janssen, Bristol Myers Squibb/Celgene, Amgen, Takeda, AbbVie, Sanofi and Oncopeptides.
Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
